|Articles|June 8, 2020
Managing the COVID-19 Drug Safety Response
Author(s)MyMeds&Me
Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.
Related Content
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
3
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu
4
The Questions You Couldn’t Ask in Time: How Agentic AI Accelerates Market Entry
5